Received May 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
bullous eruption; This serious case was reported by a other health professional and described the occurrence of bullous eruption in a 61-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 13-MAY-2026, the patient received Shingrix. On 14-MAY-2026, 1 days after receiving Shingrix, the patient experienced bullous eruption (Verbatim: bullous eruption) (serious criteria GSK medically significant). The outcome of the bullous eruption was not resolved. It was unknown if the reporter considered the bullous eruption to be related to Shingrix. The company considered the bullous eruption to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 22-MAY-2026 It was reported no other products were received by the patient. The patient experienced bullous erythematous rash in an abdominal/dermatomal distribution was observed on the contralateral side of vaccine administration, and an erythematous rash of the breast was noted on the same side (bullous eruption). The symptoms were treated. The batch number was not provided upon follow up with the reporter.; Sender's Comments: A case of Dermatitis bullous, 1 day after receiving Shingrix, in a 61-year-old female subject. Case lacks further information on medical history, concurrent conditions and laboratory data. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow up has not been received.